Predicting Antigen Presentation—What Could We Learn From a Million Peptides?

Antigen presentation lies at the heart of immune recognition of infected or malignant cells. For this reason, important efforts have been made to predict which peptides are more likely to bind and be presented by the human leukocyte antigen (HLA) complex at the surface of cells. These predictions have become even more important with the advent of next-generation sequencing technologies that enable researchers and clinicians to rapidly determine the sequences of pathogens (and their multiple variants) or identify non-synonymous genetic alterations in cancer cells. Here, we review recent advances in predicting HLA binding and antigen presentation in human cells. We argue that the very large amount of high-quality mass spectrometry data of eluted (mainly self) HLA ligands generated in the last few years provides unprecedented opportunities to improve our ability to predict antigen presentation and learn new properties of HLA molecules, as demonstrated in many recent studies of naturally presented HLA-I ligands. Although major challenges still lie on the road toward the ultimate goal of predicting immunogenicity, these experimental and computational developments will facilitate screening of putative epitopes, which may eventually help decipher the rules governing T cell recognition.

[1]  E. Mardis,et al.  A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells , 2015, Science.

[2]  Nicholas A Williamson,et al.  Secreted HLA recapitulates the immunopeptidome and allows in-depth coverage of HLA A*02:01 ligands. , 2012, Molecular immunology.

[3]  Magdalini Moutaftsi,et al.  A consensus epitope prediction approach identifies the breadth of murine TCD8+-cell responses to vaccinia virus , 2006, Nature Biotechnology.

[4]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[5]  Ruedi Aebersold,et al.  Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry. , 2015, Molecular & cellular proteomics : MCP.

[6]  Mathieu Courcelles,et al.  Comparison of the MHC I Immunopeptidome Repertoire of B‐Cell Lymphoblasts Using Two Isolation Methods , 2018, Proteomics.

[7]  J. Greenbaum,et al.  Improved methods for predicting peptide binding affinity to MHC class II molecules , 2018, Immunology.

[8]  José A. Dianes,et al.  2016 update of the PRIDE database and its related tools , 2015, Nucleic Acids Res..

[9]  Andreas Handel,et al.  Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells , 2017, Nature.

[10]  Markus Müller,et al.  Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome , 2018, bioRxiv.

[11]  Pingping Guan,et al.  EpiJen: a server for multistep T cell epitope prediction , 2006, BMC Bioinformatics.

[12]  F. Bootz,et al.  The MHC Class II Immunopeptidome of Lymph Nodes in Health and in Chemically Induced Colitis , 2017, The Journal of Immunology.

[13]  M. Nielsen,et al.  Predicted MHC peptide binding promiscuity explains MHC class I ‘hotspots’ of antigen presentation defined by mass spectrometry eluted ligand data , 2018, Immunology.

[14]  Scheherazade Sadegh-Nasseri,et al.  MHC Class II Auto-Antigen Presentation is Unconventional , 2015, Front. Immunol..

[15]  J. Utikal,et al.  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer , 2017, Nature.

[16]  Alex Rubinsteyn,et al.  Predicting Peptide-MHC Binding Affinities with Imputed Training Data , 2016, bioRxiv.

[17]  John Sidney,et al.  Examining the independent binding assumption for binding of peptide epitopes to MHC-I molecules , 2003, Bioinform..

[18]  Wei Jiang,et al.  High-throughput engineering and analysis of peptide binding to class II MHC , 2010, Proceedings of the National Academy of Sciences.

[19]  Lloyd J. Old,et al.  Cancer/testis antigens, gametogenesis and cancer , 2005, Nature Reviews Cancer.

[20]  K. Cibulskis,et al.  Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. , 2014, Blood.

[21]  Ash A. Alizadeh,et al.  Antigen Presentation Profiling Reveals Recognition of Lymphoma Immunoglobulin Neoantigens , 2017, Nature.

[22]  H. Rammensee,et al.  Autophagy promotes MHC class II presentation of peptides from intracellular source proteins , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[24]  Bjoern Peters,et al.  Deciphering the MHC-associated peptidome: a review of naturally processed ligand data , 2017, Expert review of proteomics.

[25]  Clemencia Pinilla,et al.  Derivation of an amino acid similarity matrix for peptide:MHC binding and its application as a Bayesian prior , 2009, BMC Bioinformatics.

[26]  A. Bentzen,et al.  Evolution of MHC-based technologies used for detection of antigen-responsive T cells , 2017, Cancer Immunology, Immunotherapy.

[27]  T. Schumacher,et al.  Dissection of T-cell antigen specificity in human melanoma. , 2012, Cancer research.

[28]  David Gfeller,et al.  Current tools for predicting cancer-specific T cell immunity , 2016, Oncoimmunology.

[29]  M. Mann,et al.  T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice. , 2015, Gastroenterology.

[30]  J. Neefjes,et al.  Towards a systems understanding of MHC class I and MHC class II antigen presentation , 2011, Nature Reviews Immunology.

[31]  Y. Welte,et al.  High Immunogenicity of the Human Leukocyte Antigen Peptidomes of Melanoma Tumor Cells* , 2012, The Journal of Biological Chemistry.

[32]  Timothy E. Elliott,et al.  A quantitative assay of peptide‐dependent class I assembly , 1991, European journal of immunology.

[33]  Ilan Beer,et al.  Analysis of endogenous peptides bound by soluble MHC class I molecules: a novel approach for identifying tumor‐specific antigens , 2002, European journal of immunology.

[34]  Morten Nielsen,et al.  Improved Prediction of Bovine Leucocyte Antigens (BoLA) Presented Ligands by Use of Mass-Spectrometry-Determined Ligand and in Vitro Binding Data , 2017, Journal of proteome research.

[35]  L. Stern,et al.  HLA-DM Focuses on Conformational Flexibility Around P1 Pocket to Catalyze Peptide Exchange , 2013, Front. Immunol..

[36]  J. Rossjohn,et al.  The molecular basis for peptide repertoire selection in the human leukocyte antigen (HLA) C*06:02 molecule , 2017, The Journal of Biological Chemistry.

[37]  Thomas L. Madden,et al.  Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.

[38]  T. Schumacher,et al.  High sensitivity of cancer exome-based CD8 T cell neo-antigen identification , 2014, Oncoimmunology.

[39]  N. Croft,et al.  A comprehensive analysis of peptides presented by HLA-A1. , 2015, Tissue antigens.

[40]  G. Coukos,et al.  The Length Distribution and Multiple Specificity of Naturally Presented HLA-I Ligands , 2018, The Journal of Immunology.

[41]  J. Castle,et al.  Exploiting the mutanome for tumor vaccination. , 2012, Cancer research.

[42]  S. Sadegh-Nasseri,et al.  Determinants of immunodominance for CD4 T cells. , 2015, Current opinion in immunology.

[43]  M. Nielsen,et al.  Unconventional Peptide Presentation by Major Histocompatibility Complex (MHC) Class I Allele HLA-A*02:01 , 2017, The Journal of Biological Chemistry.

[44]  S. Sadegh-Nasseri A step-by-step overview of the dynamic process of epitope selection by major histocompatibility complex class II for presentation to helper T cells , 2016, F1000Research.

[45]  Ton N. Schumacher,et al.  Targeting of cancer neoantigens with donor-derived T cell receptor repertoires , 2016, Science.

[46]  Michael R Stratton,et al.  High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma , 2014, Nature Medicine.

[47]  Morten Nielsen,et al.  Gapped sequence alignment using artificial neural networks: application to the MHC class I system , 2016, Bioinform..

[48]  J. Sidney,et al.  Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity , 2014, The Journal of experimental medicine.

[49]  A. Nesvizhskii Proteogenomics: concepts, applications and computational strategies , 2014, Nature Methods.

[50]  B. Walker,et al.  Crystal structure of HLA-B*5801 with a TW10 HIV Gag epitope reveals a novel mode of peptide presentation , 2017, Cellular &Molecular Immunology.

[51]  J. Castle,et al.  Targeting the tumor mutanome for personalized vaccination therapy , 2012, Oncoimmunology.

[52]  R. Henderson,et al.  Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. , 1992, Science.

[53]  Hans-Georg Rammensee,et al.  Unveiling the Peptide Motifs of HLA-C and HLA-G from Naturally Presented Peptides and Generation of Binding Prediction Matrices , 2017, The Journal of Immunology.

[54]  P. Kloetzel,et al.  Modeling the MHC class I pathway by combining predictions of proteasomal cleavage,TAP transport and MHC class I binding , 2005, Cellular and Molecular Life Sciences CMLS.

[55]  M. Ciudad,et al.  Composition of the HLA‐DR‐associated human thymus peptidome , 2013, European journal of immunology.

[56]  Albert J R Heck,et al.  Expanding the detectable HLA peptide repertoire using electron-transfer/higher-energy collision dissociation (EThcD) , 2014, Proceedings of the National Academy of Sciences.

[57]  Pingping Guan,et al.  MHCPred: a server for quantitative prediction of peptide-MHC binding , 2003, Nucleic Acids Res..

[58]  Peter Cresswell,et al.  Pathways of antigen processing. , 2013, Annual review of immunology.

[59]  L. Jensen,et al.  Mass Spectrometry of Human Leukocyte Antigen Class I Peptidomes Reveals Strong Effects of Protein Abundance and Turnover on Antigen Presentation* , 2015, Molecular & Cellular Proteomics.

[60]  F. Sinigaglia,et al.  Identification of a motif for HLA-DR1 binding peptides using M13 display libraries , 1992, The Journal of experimental medicine.

[61]  Z. Szallasi,et al.  Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes , 2016, Nature Biotechnology.

[62]  K Kumagai,et al.  A simple method to eliminate the antigenicity of surface class I MHC molecules from the membrane of viable cells by acid treatment at pH 3. , 1987, Journal of immunological methods.

[63]  M. Nielsen,et al.  NetMHCpan-4.0: Improved Peptide–MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data , 2017, The Journal of Immunology.

[64]  Ilan Beer,et al.  Soluble plasma HLA peptidome as a potential source for cancer biomarkers , 2010, Proceedings of the National Academy of Sciences.

[65]  J. Gartner,et al.  Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients , 2016, Nature Medicine.

[66]  A. Purcell,et al.  Revisiting the Arthritogenic Peptide Theory: Quantitative Not Qualitative Changes in the Peptide Repertoire of HLA–B27 Allotypes , 2015, Arthritis & rheumatology.

[67]  P. Kloetzel,et al.  A large fraction of HLA class I ligands are proteasome-generated spliced peptides , 2016, Science.

[68]  Jian Wang,et al.  PSSMHCpan: a novel PSSM-based software for predicting class I peptide-HLA binding affinity , 2017, GigaScience.

[69]  Mark Lindsey,et al.  Large-scale production of class I bound peptides: assigning a signature to HLA-B*1501 , 1997, Immunogenetics.

[70]  Dongsup Kim,et al.  Deep convolutional neural networks for pan-specific peptide-MHC class I binding prediction , 2017, BMC Bioinformatics.

[71]  Dario Neri,et al.  High‐resolution analysis of the murine MHC class II immunopeptidome , 2016, European journal of immunology.

[72]  Dario Neri,et al.  Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes , 2016, Cancer Immunology, Immunotherapy.

[73]  David Gfeller,et al.  Unsupervised HLA Peptidome Deconvolution Improves Ligand Prediction Accuracy and Predicts Cooperative Effects in Peptide–HLA Interactions , 2016, The Journal of Immunology.

[74]  Hans-Georg Rammensee,et al.  The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy , 2004, Cancer Immunology, Immunotherapy.

[75]  L. Stern,et al.  Measurement of Peptide Binding to MHC Class II Molecules by Fluorescence Polarization , 2014, Current protocols in immunology.

[76]  K. Garcia,et al.  The Intergenic Recombinant HLA-B∗46:01 Has a Distinctive Peptidome that Includes KIR2DL3 Ligands , 2017, Cell Reports.

[77]  J. Gartner,et al.  T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. , 2016, The New England journal of medicine.

[78]  O. Lund,et al.  The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage , 2005, Immunogenetics.

[79]  D. Neri,et al.  Membranal and Blood‐Soluble HLA Class II Peptidome Analyses Using Data‐Dependent and Independent Acquisition , 2018, Proteomics.

[80]  Gajendra P. S. Raghava,et al.  ProPred: prediction of HLA-DR binding sites , 2001, Bioinform..

[81]  Yu Shyr,et al.  Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy , 2016, Nature Communications.

[82]  Clemencia Pinilla,et al.  Measurement of MHC/Peptide Interactions by Gel Filtration or Monoclonal Antibody Capture , 2013, Current protocols in immunology.

[83]  Morten Nielsen,et al.  NetMHCcons: a consensus method for the major histocompatibility complex class I predictions , 2011, Immunogenetics.

[84]  Morten Nielsen,et al.  Immunological bioinformatics , 2005, Computational molecular biology.

[85]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[86]  M. Nielsen,et al.  Footprints of antigen processing boost MHC class II natural ligand binding predictions , 2018, bioRxiv.

[87]  A. Sewell,et al.  Real time detection of peptide–MHC dissociation reveals that improvement of primary MHC-binding residues can have a minimal, or no, effect on stability , 2011, Molecular immunology.

[88]  T. Schumacher,et al.  Generation of peptide–MHC class I complexes through UV-mediated ligand exchange , 2006, Nature Protocols.

[89]  Shabaz Mohammed,et al.  Sampling From the Proteome to the Human Leukocyte Antigen-DR (HLA-DR) Ligandome Proceeds Via High Specificity* , 2016, Molecular & Cellular Proteomics.

[90]  V. Crotzer,et al.  Autophagy and Its Role in MHC-Mediated Antigen Presentation1 , 2009, The Journal of Immunology.

[91]  D. Ferrington,et al.  Immunoproteasomes: structure, function, and antigen presentation. , 2012, Progress in molecular biology and translational science.

[92]  Stefan Tenzer,et al.  Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. , 2009, Nature immunology.

[93]  A. Prescott,et al.  Enhanced Dendritic Cell Antigen Capture via Toll-Like Receptor-Induced Actin Remodeling , 2004, Science.

[94]  E. Caron,et al.  The MHC class I peptide repertoire is molded by the transcriptome , 2008, The Journal of experimental medicine.

[95]  Chee Keong Kwoh,et al.  PREDTAP: a system for prediction of peptide binding to the human transporter associated with antigen processing , 2006, Immunome research.

[96]  Markus Müller,et al.  ‘Hotspots’ of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization , 2017, Front. Immunol..

[97]  Edward J. Collins,et al.  Three-dimensional structure of a peptide extending from one end of a class I MHC binding site , 1994, Nature.

[98]  Dario Neri,et al.  High‐sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients’ sera , 2016, Proteomics.

[99]  Gary D Bader,et al.  The multiple-specificity landscape of modular peptide recognition domains. , 2011 .

[100]  Morten Nielsen,et al.  The PickPocket method for predicting binding specificities for receptors based on receptor pocket similarities: application to MHC-peptide binding , 2009, Bioinform..

[101]  Morten Nielsen,et al.  Peptide‐MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity , 2012, European journal of immunology.

[102]  S. Rosenberg,et al.  Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.

[103]  Hidde L. Ploegh,et al.  The known unknowns of antigen processing and presentation , 2008, Nature Reviews Immunology.

[104]  H. Rammensee,et al.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.

[105]  Roman A. Zubarev,et al.  The SysteMHC Atlas project , 2017, Nucleic Acids Res..

[106]  M. Nielsen,et al.  Machine learning reveals a non‐canonical mode of peptide binding to MHC class II molecules , 2017, Immunology.

[107]  M. Lotze,et al.  Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[108]  David Gfeller,et al.  Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity , 2017, bioRxiv.

[109]  M. Maeurer,et al.  Peptide Microarray-Based Identification of Mycobacterium tuberculosis Epitope Binding to HLA-DRB1*0101, DRB1*1501, and DRB1*0401 , 2009, Clinical and Vaccine Immunology.

[110]  Anne M Evans,et al.  Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy , 2006, Proceedings of the National Academy of Sciences.

[111]  Jennifer G. Abelin,et al.  Mass Spectrometry Profiling of HLA‐Associated Peptidomes in Mono‐allelic Cells Enables More Accurate Epitope Prediction , 2017, Immunity.

[112]  Brian J. Stevenson,et al.  Sensitive and frequent identification of high avidity neo-epitope specific CD8+ T cells in immunotherapy-naive ovarian cancer , 2018, Nature Communications.

[113]  Morten Nielsen,et al.  GibbsCluster: unsupervised clustering and alignment of peptide sequences , 2017, Nucleic Acids Res..

[114]  Juan Antonio Vizcaíno,et al.  Minimal Information About an Immuno‐Peptidomics Experiment (MIAIPE) , 2018, Proteomics.

[115]  Sri H. Ramarathinam,et al.  A comprehensive analysis of constitutive naturally processed and presented HLA-C*04:01 (Cw4)-specific peptides. , 2014, Tissue antigens.

[116]  U. Şahin,et al.  Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices , 1999, Nature Biotechnology.

[117]  Morten Nielsen,et al.  Computational Tools for the Identification and Interpretation of Sequence Motifs in Immunopeptidomes , 2018, Proteomics.

[118]  Jamie K Teer,et al.  Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens , 2016, Oncotarget.

[119]  Deborah Hix,et al.  The immune epitope database (IEDB) 3.0 , 2014, Nucleic Acids Res..

[120]  T. Elliott,et al.  Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. , 1999, Journal of immunology.

[121]  F. Glaser,et al.  The Peptide Repertoire of HLA‐B27 may include Ligands with Lysine at P2 Anchor Position , 2018, Proteomics.

[122]  Sri H. Ramarathinam,et al.  Phosphorylated self-peptides alter human leukocyte antigen class I-restricted antigen presentation and generate tumor-specific epitopes , 2009, Proceedings of the National Academy of Sciences.

[123]  T. Sicheritz-Pontén,et al.  Comparative performance of the BGISEQ-500 vs Illumina HiSeq2500 sequencing platforms for palaeogenomic sequencing , 2017, GigaScience.

[124]  Alessandro Sette,et al.  Properties of MHC Class I Presented Peptides That Enhance Immunogenicity , 2013, PLoS Comput. Biol..

[125]  Bjoern Peters,et al.  Insights into HLA-Restricted T Cell Responses in a Novel Mouse Model of Dengue Virus Infection Point toward New Implications for Vaccine Design , 2011, The Journal of Immunology.

[126]  L. Stern,et al.  Evaluating the Role of HLA-DM in MHC Class II–Peptide Association Reactions , 2015, The Journal of Immunology.

[127]  T. Elliott,et al.  Assembly of MHC class I molecules analyzed in vitro , 1990, Cell.

[128]  N. Wentzensen,et al.  A systematic review of humoral immune responses against tumor antigens , 2009, Cancer Immunology, Immunotherapy.

[129]  P. Roche,et al.  The ins and outs of MHC class II-mediated antigen processing and presentation , 2015, Nature Reviews Immunology.

[130]  Purvesh Khatri,et al.  Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes , 2017, Cell.

[131]  H. Kalbacher,et al.  Self-peptides from four HLA-DR alleles share hydrophobic anchor residues near the NH2-terminal including proline as a stop signal for trimming. , 1993, Journal of immunology.

[132]  Markus Müller,et al.  High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome* , 2017, Molecular & Cellular Proteomics.

[133]  Valerio Zolla,et al.  The Dendritic Cell Major Histocompatibility Complex II (MHC II) Peptidome Derives from a Variety of Processing Pathways and Includes Peptides with a Broad Spectrum of HLA-DM Sensitivity* , 2016, The Journal of Biological Chemistry.

[134]  Chris Bailey-Kellogg,et al.  A high throughput MHC II binding assay for quantitative analysis of peptide epitopes. , 2014, Journal of visualized experiments : JoVE.

[135]  Bjoern Peters,et al.  HLA class I supertypes: a revised and updated classification , 2008, BMC Immunology.

[136]  Maria V. Tejada-Simon,et al.  Naturally Processed HLA Class II Peptides Reveal Highly Conserved Immunogenic Flanking Region Sequence Preferences That Reflect Antigen Processing Rather Than Peptide-MHC Interactions1 , 2001, The Journal of Immunology.

[137]  O. Lund,et al.  novel sequence representations Reliable prediction of T-cell epitopes using neural networks with , 2003 .

[138]  T. Schumacher,et al.  Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7 , 2008, Proceedings of the National Academy of Sciences.

[139]  David Gfeller,et al.  Uncovering new aspects of protein interactions through analysis of specificity landscapes in peptide recognition domains , 2012, FEBS letters.

[140]  S. Lemieux,et al.  Global proteogenomic analysis of human MHC class I-associated peptides derived from non-canonical reading frames , 2016, Nature Communications.

[141]  J. Drijfhout,et al.  Naturally Processed Non-canonical HLA-A*02:01 Presented Peptides* , 2014, The Journal of Biological Chemistry.

[142]  S. Lemieux,et al.  MHC class I-associated peptides derive from selective regions of the human genome. , 2016, The Journal of clinical investigation.

[143]  H. Rammensee,et al.  Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. , 1994, Journal of immunology.

[144]  Morten Nielsen,et al.  Uncovering the Peptide-Binding Specificities of HLA-C: A General Strategy To Determine the Specificity of Any MHC Class I Molecule , 2014, The Journal of Immunology.

[145]  Jimmy Lin,et al.  Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells , 2013, Nature Medicine.

[146]  Gary D. Bader,et al.  MUSI: an integrated system for identifying multiple specificity from very large peptide or nucleic acid data sets , 2011, Nucleic acids research.

[147]  José A. Dianes,et al.  2016 update of the PRIDE database and its related tools , 2016, Nucleic Acids Res..

[148]  Xiaohui Xie,et al.  HLA class I binding prediction via convolutional neural networks , 2017, bioRxiv.

[149]  Eilon Barnea,et al.  Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy * , 2016, Molecular & Cellular Proteomics.

[150]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[151]  P. Cresswell,et al.  Cellular mechanisms governing cross-presentation of exogenous antigens , 2004, Nature Immunology.

[152]  Charles H. Yoon,et al.  An immunogenic personal neoantigen vaccine for patients with melanoma , 2017, Nature.

[153]  M. Nielsen,et al.  NetMHCstab – predicting stability of peptide–MHC‐I complexes; impacts for cytotoxic T lymphocyte epitope discovery , 2014, Immunology.

[154]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[155]  Søren Buus,et al.  Functional recombinant MHC class II molecules and high-throughput peptide-binding assays , 2009, Immunome research.

[156]  Z. Szallasi,et al.  An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes , 2017, Front. Immunol..

[157]  M. Mann,et al.  Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry , 2016, Nature Communications.

[158]  K. Rock,et al.  Specialized proteasome subunits play an essential role in thymic selection of CD8+ T cells , 2016, Nature Immunology.

[159]  Z. Modrušan,et al.  Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing , 2014, Nature.

[160]  Alexandre M J J Bonvin,et al.  Extended O-GlcNAc on HLA Class-I-Bound Peptides. , 2015, Journal of the American Chemical Society.

[161]  Morten Nielsen,et al.  Toxoplasma gondii peptide ligands open the gate of the HLA class I binding groove , 2016, eLife.

[162]  M. Nielsen,et al.  The Length Distribution of Class I–Restricted T Cell Epitopes Is Determined by Both Peptide Supply and MHC Allele–Specific Binding Preference , 2016, The Journal of Immunology.

[163]  Markus Wulf,et al.  Identification of human MHC class I binding peptides using the iTOPIA- epitope discovery system. , 2009, Methods in molecular biology.

[164]  F. Chisari,et al.  Role of Immunoproteasome Catalytic Subunits in the Immune Response to Hepatitis B Virus , 2006, Journal of Virology.

[165]  F. Pazos,et al.  A Molecular Basis for the Presentation of Phosphorylated Peptides by HLA-B Antigens* , 2016, Molecular & Cellular Proteomics.

[166]  Hans-Georg Rammensee,et al.  Integrated functional genomics approach for the design of patient-individual antitumor vaccines. , 2002, Cancer research.

[167]  Bjoern Peters,et al.  Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries , 2008, Immunome research.

[168]  Albert J R Heck,et al.  Arginine (Di)methylated Human Leukocyte Antigen Class I Peptides Are Favorably Presented by HLA-B*07. , 2017, Journal of proteome research.

[169]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[170]  Maxim N. Artyomov,et al.  Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens , 2014, Nature.

[171]  J. Voorberg,et al.  Analysis of the HLA‐DR peptidome from human dendritic cells reveals high affinity repertoires and nonconventional pathways of peptide generation , 2017, Journal of leukocyte biology.

[172]  James Robinson,et al.  The IPD and IMGT/HLA database: allele variant databases , 2014, Nucleic Acids Res..

[173]  Ralf Zimmer,et al.  Improved Ribo-seq enables identification of cryptic translation events , 2018, Nature Methods.

[174]  John Sidney,et al.  A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach , 2008, PLoS Comput. Biol..

[175]  Morten Nielsen,et al.  Simultaneous alignment and clustering of peptide data using a Gibbs sampling approach , 2013, Bioinform..

[176]  K. Rock,et al.  The Biology and Underlying Mechanisms of Cross-Presentation of Exogenous Antigens on MHC-I Molecules. , 2017, Annual review of immunology.

[177]  Morten Nielsen,et al.  NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction , 2009, BMC Bioinformatics.

[178]  Rachel Karchin,et al.  Prediction of peptide binding to MHC Class I proteins in the age of deep learning , 2017 .

[179]  Eilon Barnea,et al.  The Peptidome of Behçet's Disease–Associated HLA–B*51:01 Includes Two Subpeptidomes Differentially Shaped by Endoplasmic Reticulum Aminopeptidase 1 , 2015, Arthritis & rheumatology.

[180]  Sébastien Lemieux,et al.  The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation , 2011, Molecular systems biology.

[181]  N. Hacohen,et al.  HLA-Binding Properties of Tumor Neoepitopes in Humans , 2014, Cancer Immunology Research.

[182]  Morten Nielsen,et al.  Pan-Specific Prediction of Peptide–MHC Class I Complex Stability, a Correlate of T Cell Immunogenicity , 2016, The Journal of Immunology.

[183]  D. Egan,et al.  High-throughput T-cell epitope discovery through MHC peptide exchange. , 2009, Methods in molecular biology.

[184]  Søren Buus,et al.  Real-time, high-throughput measurements of peptide-MHC-I dissociation using a scintillation proximity assay. , 2011, Journal of immunological methods.

[185]  S. Henikoff,et al.  Amino acid substitution matrices from protein blocks. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[186]  G. Coukos,et al.  The C-terminal extension landscape of naturally presented HLA-I ligands , 2017, Proceedings of the National Academy of Sciences.

[187]  Sri H. Ramarathinam,et al.  MHC-I peptides get out of the groove and enable a novel mechanism of HIV-1 escape , 2017, Nature Structural &Molecular Biology.